Board to consider declaration of interim dividend, if any, for the financial year 2025-26.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has informed exchanges that its Board of Directors will meet on Thursday, July 31, 2025. The agenda includes approving the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26). The Board will also consider the declaration of an interim dividend, if any, for the financial year 2025-26. The trading window for dealing in company securities remains closed until August 2, 2025. No specific financial numbers have been disclosed in this intimation.
This is a routine pre-results announcement. Investors should watch for the Q1 results and any dividend declaration on July 31, which could be positive for shareholders if an interim dividend is announced. The stock may see some activity around the results date.